Author Identifier

Zheng Guo: https://orcid.org/0000-0003-2105-4537

Document Type

Journal Article

Publication Title

Frontiers in Immunology

Volume

16

Publisher

Frontiers

School

Centre for Precision Health / School of Medical and Health Sciences

Publication Unique Identifier

10.3389/fimmu.2025.1532145

RAS ID

78841

Comments

Wang, H., Li, H., Guo, Z., Hou, H., Hou, H., & Chen, B. (2025). Immunoglobulin GN-Glycome as a biomarker of mortality risk in Escherichia coli induced sepsis. Frontiers in Immunology, 16, 1532145. https://doi.org/10.3389/fimmu.2025.1532145

Abstract

Background: Sepsis is a life-threatening syndrome caused by an imbalance in the inflammatory response to an infection that can lead to a high mortality rate. Escherichia coli is a common pathogen that causes sepsis. The role of immunoglobulin G N-glycome in estimating the mortality in patients with sepsis remains unknown. This study aims to reveal the clinical application of immunoglobulin G N-glycome as a potentially novel biomarker to predict mortality risk in Escherichia coli-induced sepsis. Methods: The serum immunoglobulin G N-glycome levels in 100 adult septic patient serum samples on the day of intensive care unit (ICU) admission, and 100 healthy volunteers were measured and analyzed. Immunoglobulin G N-glycome was compared with existing risk scores on predicting in-hospital death. Results: We identified that the fucosylation level was significantly decreased in patients. Importantly, bisecting GlcNAc, sialylation, and galactosylation have different levels between sepsis and control groups. In addition, the AUC values of the SOFA score combined with GP4, GP5, and GP9 were 0.76 (95%CI: 0.61 to 0.90), 0.58 (95%CI: 0.40 to 0.7) and 0.57 (95%CI: 0.38 to 0.76). The AUC value of the SOFA score combined with GP4 and GP7 was 0.85 (95%CI: 0.76 to 0.93) in predicting in-hospital mortality in patients with sepsis. Conclusions: Immunoglobulin G N-glycome concentrations at ICU admission are valuable for predicting the in-hospital mortality risk of patients with sepsis, suggesting that immunoglobulin G N-glycome may be a novel biomarker.

DOI

10.3389/fimmu.2025.1532145

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

 
COinS